GlobeNewsWire
31 Dec 2025, 11:55 UTC · 40w ago
Verdict
Headline takes no side. We score AXSM +0.80 — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
Which stocks this story touches
More positive than 89% of ticker scores this week
The company received FDA support for its AXS-12 NDA submission and holds Orphan Drug Designation for the treatment of narcolepsy.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
2h ago
+11.6%
Price agrees with the score
$166.00 vs $148.79 close before publication (Dec 30) · not market-adjusted
AXSM chart →
